keyword
MENU ▼
Read by QxMD icon Read
search

"Phosphate binders"

keyword
https://www.readbyqxmd.com/read/29311459/-low-continuity-rate-of-sucroferric-oxyhydroxide-among-japanese-hemodialysis-patients-with-high-phosphate-binder-pill-burden
#1
Satoru Mitsuboshi, Hitoshi Yamada, Kazuhiko Nagai, Hideo Okajima
 This prospective observational study was conducted to evaluate the continuity, efficacy, and tolerability of sucroferric oxyhydroxide (SO) among hemodialysis (HD) patients who switched to SO from sevelamer hydrochloride (SH) or bixalomer (BX). Participants were 9 HD patients in Kaetsu Hospital who had been receiving more than 9 tablets/d of SH or BX and were switched to SO 750 mg/d. All the participants were men. Over a 6-month observational period, 6 of the 9 patients (67%) discontinued SO because of adverse events, including diarrhea, atheroma, and polycythemia...
2018: Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan
https://www.readbyqxmd.com/read/29302869/lanthanum-induced-mucosal-alterations-in-the-stomach-lanthanum-gastropathy-a-comparative-study-using-an-animal-model
#2
Kei Yabuki, Joji Haratake, Yojiro Tsuda, Eisuke Shiba, Hiroshi Harada, Kenji Yorita, Kazuyoshi Uchihashi, Atsuji Matsuyama, Keiji Hirata, Masanori Hisaoka
Lanthanum (La) carbonate (LC) is one of the most potent phosphate binders that prevents the elevation of serum phosphate levels in patients with end-stage renal diseases undergoing dialysis. LC binds strongly to dietary phosphate and forms insoluble complexes that pass through the gastrointestinal tract. La deposition in patients treated with LC is a recently documented finding particularly observed in gastric mucosa. We herein describe the detailed gastric mucosal lesions in 45 LC-treated patients and address the potential underlying pathologic mechanism using oral LC administration in rats...
January 4, 2018: Biological Trace Element Research
https://www.readbyqxmd.com/read/29295646/intensified-treatment-of-hyperphosphatemia-associated-with-reduction-in-parathyroid-hormone-in-patients-on-maintenance-hemodialysis
#3
Lan Chen, Jin-Xuan He, Ying-Ying Chen, Yi-Sheng Ling, Chun-Hua Lin, Tian-Jun Guan
BACKGROUND: This study investigated the therapeutic effect of intensive phosphorus-lowering therapy on intact-parathyroid hormone (iPTH) levels in hemodialysis patients. METHODS: Ninety-five hemodialysis patients with serum phosphorus ≥1.78 mmol/L and iPTH ≥300 pg/dL were apportioned to either the treatment or control group (n = 43 and 52, respectively) based on patient commitment to treatment. The treatment group was given phosphorus-lowering therapies with phosphate binders (lanthanum, sevelamer or/and calcium reagent) combined with dietary phosphate restriction and intensified hemodialysis...
November 2018: Renal Failure
https://www.readbyqxmd.com/read/29238578/bone-eating-kidney-disease
#4
Abhilash Koratala, Muhannad Leghrouz, Amir Kazory
In the current era of early detection of chronic kidney disease and efficient therapeutic options for management of its complications, skeletal manifestations of renal hyperparathyroidism are increasingly rare. A 31-year-old female patient presented for evaluation of severe pain in the left forearm, right hand, right knee, right hip, and lower back following a fall sustained 3 days prior to presentation. She had a history of end-stage renal disease and received maintenance hemodialysis. Review of the medical records revealed that she had poor compliance with her diet, medications, and dialysis treatments...
2017: SAGE Open Medical Case Reports
https://www.readbyqxmd.com/read/29224957/stuck-in-a-bind-with-phosphate-binders
#5
EDITORIAL
Bryan Kestenbaum, Bruce M Psaty
No abstract text is available yet for this article.
December 7, 2017: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/29195858/phosphate-binder-use-in-us-dialysis-patients-prevalence-costs-evidence-and-policies
#6
Wendy L St Peter, Lori D Wazny, Eric D Weinhandl
Medicare costs for phosphate binders for US dialysis patients and patients with chronic kidney disease enrolled in Medicare Part D exceeded $1.5 billion in 2015. Previous data have shown that Part D costs for mineral and bone disorder medications increased faster than costs for all Part D medications for dialysis patients. Despite extensive use of phosphate binders and escalating costs, conclusive evidence is lacking that they improve important clinical end points in dialysis patients or non-dialysis-dependent patients with chronic kidney disease...
November 28, 2017: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/29181658/effect-of-ferric-citrate-hydrate-on-fgf23-and-pth-levels-in-patients-with-non-dialysis-dependent-chronic-kidney-disease-with-normophosphatemia-and-iron-deficiency
#7
Akira Iguchi, Suguru Yamamoto, Mihoko Yamazaki, Kazuyuki Tasaki, Yasushi Suzuki, Junichiro James Kazama, Ichiei Narita
BACKGROUND: In patients with normophosphatemia with chronic kidney disease (CKD), fibroblast growth factor 23 (FGF23) and parathyroid hormone (PTH) increase urinary phosphate excretion while maintaining serum phosphate within the normal range. Recent reports have shown that, in this stage, phosphate binders do not decrease serum FGF23 and PTH levels. Iron deficiency promotes transcription of FGF23 and iron-supplementation for iron deficiency decreases serum FGF23 levels. We hypothesized that ferric citrate hydrate, an iron-based phosphate binder, will decrease serum FGF23 levels in patients with non-dialysis-dependent CKD with normophosphatemia and iron deficiency...
November 27, 2017: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/29174672/-aluminic-intoxication-in-chronic-hemodialysis-a-diagnosis-rarely-evoked-nowadays-clinical-case-and-review-of-the-literature
#8
Alexandre Seidowsky, Emmanuel Dupuis, Tilman Drueke, Serge Dard, Ziad A Massy, Bernard Canaud
Aluminum intoxication in chronic hemodialysis patients has virtually vanished over the last decade. Therefore, the diagnosis is rarely advocated at present. Aluminum intoxication in dialysis patients associates to different degrees with dialysis encephalopathy, bone disorders and microcytic anemia. We report here the observation of a patient receiving intermittent hemodialysis therapy who presented with acute encephalopathy. It turned out to be caused by aluminum intoxication secondary to a defect in dialysis water treatment...
November 22, 2017: Néphrologie & Thérapeutique
https://www.readbyqxmd.com/read/29159529/plasma-p-cresol-lowering-effect-of-sevelamer-in-non-dialysis-ckd-patients-evidence-from-a-randomized-controlled-trial
#9
Eleonora Riccio, Massimo Sabbatini, Dario Bruzzese, Lucia Grumetto, Cristina Marchetiello, Maria Amicone, Michele Andreucci, Bruna Guida, Davide Passaretti, Giacomo Russo, Antonio Pisani
BACKGROUND: The accumulation of p-cresol, a metabolic product of aromatic amino acids generated by intestinal microbiome, increases the cardiovascular risk in chronic kidney disease (CKD) patients. Therefore, therapeutic strategies to reduce plasma p-cresol levels are highly demanded. It has been reported that the phosphate binder sevelamer (SEV) sequesters p-cresol in vitro, while in vivo studies on dialysis patients showed controversial results. Aim of our study was to evaluate the effect of SEV on p-cresol levels in non-dialysis CKD patients...
November 20, 2017: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/29148025/a-3-day-diary-of-dietary-protein-and-calorie-intake-by-serum-phosphate-concentration-and-binder-use-in-hemodialysis-patients
#10
Meiry J S Araújo, Luciana F Silva, Maria T S Martins, Cacia M Matos, Marcelo B Lopes, Rilma F S Santos, LarissaS Santos, Angiolina C Kraychete, Márcia T S Martins, Fernanda A Silva, Antonio A Lopes
INTRODUCTION: The use of phosphate binders to control hyperphosphatemia may allow diets less restricted in protein and calories for maintenance hemodialysis (MHD) patients. The study compared intakes of protein, calorie and phosphate among MHD patients with different serum phosphate concentrations, taking into account binder use. The hypothesis was that low serum phosphate would be associated with low intakes of protein and calories only in patients not on binders. METHODS: A cross-sectional study of 443 patients enrolled in the Prospective Study of the Prognosis of Chronic Hemodialysis Patients (PROHEMO) in Salvador, Brazil, with stratified sampling on serum phosphate: ≤3...
November 4, 2017: International Journal of Artificial Organs
https://www.readbyqxmd.com/read/29074818/randomized-clinical-trial-of-sevelamer-carbonate-on-serum-klotho-and-fibroblast-growth-factor-23-in-ckd
#11
Sophie Liabeuf, Jean-Philippe Ryckelynck, Najeh El Esper, Pablo Ureña, Christian Combe, Bertrand Dussol, Denis Fouque, Philippe Vanhille, Luc Frimat, Eric Thervet, Romuald Mentaverri, Dominique Prié, Gabriel Choukroun
BACKGROUND AND OBJECTIVES: Epidemiologic studies suggest that higher serum phosphaturic hormone fibroblast growth factor 23 levels are associated with increase morbidity and mortality. The aim of the FGF23 Reduction Efficacy of a New Phosphate Binder in CKD Trial was to evaluate the effect of sevelamer carbonate on serum C-terminal fibroblast growth factor 23 levels in normophosphatemic patients with CKD stage 3b/4. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Patients with CKD, eGFR between 45 and 15 ml/min per 1...
December 7, 2017: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/29064180/a-service-review-to-assess-if-innovative-intensive-phosphate-dietary-education-can-help-reduce-phosphate-levels-to-the-recommended-range-in-a-hemodialysis-population
#12
Eileen A Duff, Fiona M Chawke
INTRODUCTION: Studies suggest that hemodialysis (HD) patients are less likely to adhere to phosphate dietary restriction than to potassium, sodium, or fluid restriction. It is particularly important that dietary education is provided appropriately, consistently, and reinforced regularly to encourage compliance with diet and phosphate-binder regimens. Patient awareness of the consequences of a chronically raised phosphate and its treatment is associated with lower serum phosphate levels...
October 2017: Hemodialysis International
https://www.readbyqxmd.com/read/29064176/calciphylaxis-after-parathyroidectomy
#13
Sathish Karmegam, Anupkumar Shetty
A 60-year-old African American man with end stage renal disease on hemodialysis (HD) for the past 2.5 years developed severe hyperparathyroidism. Other past medical history included atrial fibrillation, type II diabetes mellitus, hypertension, gout, pericardial effusion needing pericardial window, deep vein thrombosis, mitral insufficiency, and cardiomyopathy with implantable cardioversion device placement. His parathyroid hormone (PTH) level peaked at 4,191 pg/mL despite being on cinacalcet, sevelamer, and paricalcitol...
October 2017: Hemodialysis International
https://www.readbyqxmd.com/read/29064141/the-role-of-dietary-phosphate-restriction-in-chronic-kidney-disease
#14
Grahame J Elder, Avya Malik, Kelly Lambert
BACKGROUND AND OBJECTIVES: Patients with progressive chronic kidney disease (CKD) develop positive phosphate balance that is associated with increased cardiovascular risk and mortality. Modification of dietary phosphate is a commonly used strategy to improve outcomes but is complicated by the need for adequate dietary protein. Surprisingly, the evidence for patient-level benefits from phosphate restriction is tenuous, and the justification for using any phosphate binder for pre-dialysis patients is questionable...
October 24, 2017: Nephrology
https://www.readbyqxmd.com/read/29063671/magnesium-supplementation-a-consideration-in-dialysis-patients
#15
EDITORIAL
Mugurel Apetrii, Adrian Covic, Ziad A Massy
Even though disorders of magnesium (Mg) balance are common in dialyzed patients, this cation is often neglected. Many factors interfere with serum magnesium including diet, medications (eg, antacids or phosphate binders), and the dialysis prescription. Mg supplementation may help reduce serum phosphate concentration, PTH, and interfere with vascular calcification and bone mineralization. It could also decrease the all-cause and cardiovascular mortalities, although the results of current studies are conflicting...
January 2018: Seminars in Dialysis
https://www.readbyqxmd.com/read/29058057/effects-of-lanthanum-carbonate-on-coronary-artery-calcification-and-cardiac-abnormalities-after-initiating-hemodialysis
#16
Hideki Fujii, Keiji Kono, Kentaro Nakai, Shunsuke Goto, Tatsuya Nishii, Atsushi Kono, Shinichi Nishi
It is known that calcium-containing phosphate binders are more closely associated with the progression of vascular calcification than non-calcium-containing phosphate binders. In this study, we investigated the effect of the non-calcium-containing phosphate binder, lanthanum carbonate on the progression of coronary artery calcification and cardiovascular abnormalities compared to that of calcium-containing phosphate binder in chronic kidney disease patients during the early period after initiating hemodialysis...
October 20, 2017: Calcified Tissue International
https://www.readbyqxmd.com/read/29044930/effect-of-incident-nocturnal-home-hemodialysis-versus-incident-continuous-ambulatory-peritoneal-dialysis-on-employment-rate-clinical-and-laboratory-outcomes-a-1-year-retrospective-observation-study
#17
John Wing Li, Joseph Ho Sing Wong, Wai Leung Chak, Ka Foon Chau
INTRODUCTION: While studies demonstrated favorable outcomes of nocturnal home hemodialysis (NHHD), direct comparison on employment rate, clinical and laboratory outcomes between the NHHD and continuous ambulatory peritoneal dialysis (CAPD) had not been previously performed. METHODS: A 1-year retrospective observation study was performed in 20 incidents alternate night NHHD and 81 incident CAPD patients of Chinese ethnicity, who were sex, diabetic status, and Charlson comorbidity index matched, but not age due to our center's age limit for NHHD enrollment...
October 18, 2017: Hemodialysis International
https://www.readbyqxmd.com/read/28993865/two-year-cortical-and-trabecular-bone-loss-in-ckd-5d-biochemical-and-clinical-predictors
#18
H H Malluche, M-C Monier-Faugere, G Blomquist, D L Davenport
This prospective two-year study of patients on chronic dialysis measured changes in bone mineral density (BMD). Patients with higher baseline BMD and shorter dialysis vintage lost more bone. Treatment with anti-hypertensives acting on the central nervous system was protective against bone loss. Baseline serum levels of sclerostin and bone-specific alkaline phosphatase predicted bone loss. INTRODUCTION: This prospective 2-year study of chronic kidney disease on dialysis (CKD-5D) patients assessed trabecular and cortical bone loss at the hip and spine and examined potential demographic, clinical, and serum biochemical predictors of bone loss...
October 9, 2017: Osteoporosis International
https://www.readbyqxmd.com/read/28970367/a-pilot-study-of-okkidney-a-phosphate-counting-application-in-patients-on-peritoneal-dialysis
#19
Rameez Imtiaz, Katherine Atkinson, Julien Guerinet, Kumanan Wilson, Jullie Leidecker, Deborah Zimmerman
BACKGROUND: Hyperphosphatemia is associated with adverse outcomes in patients treated with peritoneal dialysis (PD). We have shown that a fixed meal phosphate binder dosing schedule is not appropriate. The purpose of this study was to evaluate the beta version of OkKidney, a phosphate counting app that matches meal phosphate content with binder dose. METHODS: A convenience sample of adult patients treated with PD completed a pre-survey that included the technology readiness index (TRI 2...
September 28, 2017: Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
https://www.readbyqxmd.com/read/28941764/kdoqi-us-commentary-on-the-2017-kdigo-clinical-practice-guideline-update-for-the-diagnosis-evaluation-prevention-and%C3%A2-treatment-of-chronic-kidney-disease-mineral-and-bone%C3%A2-disorder-ckd-mbd
#20
Tamara Isakova, Thomas L Nickolas, Michelle Denburg, Sri Yarlagadda, Daniel E Weiner, Orlando M Gutiérrez, Vinod Bansal, Sylvia E Rosas, Sagar Nigwekar, Jerry Yee, Holly Kramer
Chronic kidney disease-mineral and bone disorder (CKD-MBD) encompasses laboratory and bone abnormalities and vascular calcification and has deleterious effects on clinical outcomes. KDOQI (Kidney Disease Outcomes Quality Initiative), an initiative of the National Kidney Foundation, addressed this issue with the publication of a clinical practice guideline for bone metabolism and disease in CKD in 2003, and 2 years later, a new definition and classification scheme for CKD-MBD was developed following a KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference...
December 2017: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
keyword
keyword
119826
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"